Close menu




Biotech

Photo credits: pixabay.com

Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST

BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!

  • AI
  • Biotechnology
  • Fuelcells
  • manufacturing

The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?

Read

Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST

Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation

  • Biotechnology
  • Biotech
  • Pharma
  • Takeover

While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.

Read

Commented by Stefan Feulner on October 13th, 2025 | 07:35 CEST

BioNxt Solutions – Attack on new highs

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
  • Cancer

After global stock markets had been on an upward trajectory in recent weeks, US President Donald Trump caused some irritation with a post on his social media platform, "Truth Social." The escalating trade dispute with China, the world's second-largest economy, caused the already overvalued markets to falter. The DAX lost just under 1.8% at the end of the week, while the Nasdaq technology index suffered significantly more, losing just under 4.3%. In the coming weeks, stock picking is likely to take center stage. Against this backdrop, BioNxt Solutions, a life sciences company specializing in innovative technologies for next-generation drug delivery, was able to shine with fundamental milestones and buck the negative trend.

Read

Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST

AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec

  • AI
  • Biotechnology
  • Biotech

The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.

Read

Commented by Carsten Mainitz on October 9th, 2025 | 07:35 CEST

BioNxt Solutions, Bayer, Evotec – Enormous upside! The interface of biotech and pharmaceuticals!

  • Biotechnology
  • Biotech
  • Pharma

The global rise in lifestyle diseases such as diabetes, obesity, multiple sclerosis (MS), and MASH (metabolic fatty liver disease) is driving enormous growth in the healthcare sector. The market for cancer therapies is also expanding rapidly. Meanwhile, the M&A landscape is developing dynamically: large pharmaceutical companies need to act as patent protections expire, securing their pipeline through acquisitions and partnerships. Areas offering innovative drugs or novel delivery methods are especially attractive. This is where a promising second-tier stock comes into play.

Read

Commented by André Will-Laudien on October 8th, 2025 | 07:30 CEST

BioNxt Solutions – A small biotech gem with huge potential

  • Biotechnology
  • Biotech
  • Innovations
  • Investments
  • Cancer

Modern medicine is undergoing a paradigm shift - and BioNxt Solutions could emerge as one of its key pioneers. The German-Canadian biotech company is developing innovative drug delivery platforms designed to make existing medications more effective, safer, and more patient-friendly. Whether for obesity, multiple sclerosis, or cancer, BioNxt is targeting several multi-billion-dollar markets with disruptive potential. Backed by patented technologies and an agile development strategy, BioNxt is laying the foundation for above-average growth and attractive licensing models. For investors, this could be a rare chance to get in early on what could be the next big thing in healthcare innovation.

Read

Commented by Stefan Feulner on October 7th, 2025 | 07:35 CEST

AMD, NetraMark, Adobe – AI latecomers with significant catch-up potential

  • AI
  • Biotechnology
  • Biotech
  • Software
  • Technology

The market is currently hotly debating when the AI bubble will finally burst. Investors are becoming increasingly nervous, as the valuations of many companies, such as Palantir and Nvidia, are at levels seen just before the dot-com bubble in the early 2000s. However, not all companies related to artificial intelligence are overvalued. Especially in niche segments, there are still hidden gems to be found that have the potential to multiply in value.

Read

Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST

Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play

  • Biotechnology
  • Biotech
  • Pharma
  • Innovations
  • Cancer

The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.

Read

Commented by Nico Popp on October 6th, 2025 | 07:20 CEST

Biotech: Small innovations, big impact with Teva Pharmaceutical, BioNxt and Lonza Group

  • Biotechnology
  • Biotech
  • Pharma

Anyone investing in biotech hopes to have the next big breakthrough in their portfolio: active ingredients that revolutionize everything, technologies that make a difference. In reality, however, biotechnology is characterized by many small but meaningful improvements. From an investor's perspective, it is also worth keeping an eye on these incremental advances. The reason: while the search for new, groundbreaking active ingredients is often a hit-or-miss business, small advances make it possible to generate consistent returns with relatively low capital expenditure. We present three promising business models that demonstrate the value-creation potential of incremental innovation.

Read

Commented by Stefan Feulner on October 6th, 2025 | 07:05 CEST

Novo Nordisk, FuelCell Energy and Almonty Industries stage strong rebound

  • Mining
  • Tungsten
  • Defense
  • Fuelcells
  • Biotechnology

While many analysts are concerned about high valuations on the global stock markets, with the Warren Buffett indicator at a historic high, even exceeding its value before the dot-com bubble, the markets continue to rise from one high to the next. In fact, several companies staged a strong rebound last week, which is likely to pave the way for further gains by generating fresh buy signals.

Read